3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Prostatic Neoplasms, Castration-Resistant
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Interventions
pembrolizumab
17
Specimen Handling
16
Magnetic Resonance Spectroscopy
11
Biopsy
11
Paclitaxel
7
Carboplatin
7
trastuzumab deruxtecan
6
Pemetrexed
6
Nivolumab
6
Irinotecan
6
Fulvestrant
6
Leucovorin
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
palbociclib
4
Radiosurgery
4
Oxaliplatin
4
Letrozole
4
Cisplatin
4
Cetuximab
4
olaparib
3
durvalumab
3
Taxes
3
Ipilimumab
3
Docetaxel
3
sacituzumab govitecan
2
ribociclib
2
neratinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
abiraterone
×
30 days
×
Clear all
NCT06863272
2026-05-29
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled